In a study conducted on pancreatic cancer models, they developed trivalent CAR T-cells that targets prostate stem cell antigen (PSA), IL-2, and transforming growth factor-B to improve CAR-T cell migration towards the cancer site and overcome the immunosuppressive environment [56]. Here, IL2 is linked to cancer.